Travere Therapeutics' Equity Average rose 794.53% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 794.53%. This contributed to the annual value of $129.9 million for FY2024, which is 6.66% up from last year.
Per Travere Therapeutics' latest filing, its Equity Average stood at $53.2 million for Q3 2025, which was up 62.13% from $32.8 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Equity Average ranged from a high of $347.5 million in Q2 2021 and a low of -$7.7 million during Q3 2024.
For the 3-year period, Travere Therapeutics' Equity Average averaged around $93.4 million, with its median value being $53.2 million (2025).
Per our database at Business Quant, Travere Therapeutics' Equity Average tumbled by 103.86% in 2024 and then soared by 794.53% in 2025.
Quarterly analysis of 5 years shows Travere Therapeutics' Equity Average stood at $304.7 million in 2021, then tumbled by 76.45% to $71.8 million in 2022, then skyrocketed by 234.83% to $240.3 million in 2023, then crashed by 94.04% to $14.3 million in 2024, then soared by 794.53% to $53.2 million in 2025.
Its last three reported values are $53.2 million in Q3 2025, $32.8 million for Q2 2025, and $46.0 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value